Spero Therapeutics announced on October 16, 2024, a poster presentation at IDWeek 2024 detailing in vitro data for SPR719, the active moiety of SPR720. The presentation highlighted the compound's low propensity for the development of resistance in NTM-PD MAC strains.
The study confirmed SPR719's high potency against both macrolide susceptible and resistant MAC strains. Importantly, these characteristics were maintained when SPR719 was combined with current standard of care antibiotics used in NTM-PD treatment.
This data suggests a potential benefit for SPR720 in prolonged combination regimens typical for NTM-PD, where resistance mechanisms can spontaneously manifest. The findings underscore an important aspect of SPR719’s activity against MAC NTM-PD.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.